IMCR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

107.82M

+28.28%

-0.240

-241.16%

109.60M

+16.75%

-0.188

-59.96%

112.42M

+14.76%

-0.106

-205.71%

Estimates Revision

The market is revising Upward the revenue expectations for Immunocore Holdings plc (IMCR) for FY2025, with the revenue forecasts being adjusted by 1.33% over the past three months. During the same period, the stock price has changed by 1.85%.

Revenue Estimates for FY2025

Revise Upward

+1.33%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-54.15%

In Past 3 Month

Stock Price

Go Up

+1.85%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast IMCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMCR is 63.33 USD with a low forecast of 36.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

36.00

Averages

63.33

High

100.00

Current: 0.000

Low

36.00

Averages

63.33

High

100.00

Morgan Stanley

Sean Laaman

Equal Weight

maintain

$36 -> $40

2026-01-08

New

Reason

Morgan Stanley

Sean Laaman

Price Target

$36 -> $40

2026-01-08

New

maintain

Equal Weight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on Immunocore to $40 from $36 and keeps an Equal Weight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.

UBS

Sell -> Buy

upgrade

$24 -> $55

2026-01-07

New

Reason

UBS

Price Target

$24 -> $55

2026-01-07

New

upgrade

Sell -> Buy

Reason

UBS upgraded Immunocore (IMCR) to Buy from Sell with a price target of $55, up from $24, as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Mizuho

Graig Suvannavejh

Neutral

maintain

$36 -> $37

2025-11-10

Reason

Mizuho

Graig Suvannavejh

Price Target

$36 -> $37

2025-11-10

maintain

Neutral

Reason

Mizuho analyst Graig Suvannavejh raised the firm's price target on Immunocore to $37 from $36 and keeps a Neutral rating on the shares following the Q3 report.

Morgan Stanley

Sean Laaman

Equal Weight

maintain

$34 -> $36

2025-11-10

Reason

Morgan Stanley

Sean Laaman

Price Target

$34 -> $36

2025-11-10

maintain

Equal Weight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on Immunocore to $36 from $34 and keeps an Equal Weight rating on the shares.

Wells Fargo

Eva Fortea Verdejo

Overweight

initiated

$60

2025-10-31

Reason

Wells Fargo

Eva Fortea Verdejo

Price Target

$60

2025-10-31

initiated

Overweight

Reason

Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Immunocore with an Overweight rating and $60 price target. The firm believes Kimmtrak "provides a good floor value" for the stock and indication expansion opportunities could offer upside over the next 12 months. There is room for further penetration, especially in the community setting, the analyst tells investors in a research note.

Guggenheim

Neutral

initiated

2025-09-17

Reason

Guggenheim

Price Target

2025-09-17

initiated

Neutral

Reason

Guggenheim assumed coverage of Immunocore with a Neutral rating. The company is a pioneer of the TCR therapeutics category with a solid commercial foundation in Kimmtrak - the only FDA approved systemic therapy for metastatic uveal melanoma and a $400M drug which has consistently topped the Street expectations since its launch in 2022, the analyst tells investors in a research note. Looking ahead to the next leg of growth however, the firm sees fewer sources of commercial outperformance for Kimmtrak as U.S. mUM market penetration continues to plateau, contributions from new ex-US launches taper, and real-world duration of therapy is fully appreciated, Guggenheim added.

Valuation Metrics

The current forward P/E ratio for Immunocore Holdings PLC (IMCR.O) is -69.00, compared to its 5-year average forward P/E of -45.77. For a more detailed relative valuation and DCF analysis to assess Immunocore Holdings PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-45.77

Current PE

-69.00

Overvalued PE

16.32

Undervalued PE

-107.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-56.86

Current EV/EBITDA

-23.62

Overvalued EV/EBITDA

80.14

Undervalued EV/EBITDA

-193.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

15.37

Current PS

3.84

Overvalued PS

30.98

Undervalued PS

-0.24

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IMCR News & Events

Events Timeline

No data

News

1.0

2025-11-10Newsfilter

Immunocore to Showcase at Upcoming Investor Events

4.0

2025-10-22Benzinga

HC Wainwright & Co. Affirms Buy Rating for Immunocore Holdings, Keeps $100 Price Target Intact

4.0

2025-10-21Yahoo Finance

H.C. Wainwright Maintains Positive Outlook on Immunocore Holdings plc (IMCR)

People Also Watch

Frequently Asked Questions

What is Immunocore Holdings PLC (IMCR) stock price today?

The current price of IMCR is 33 USD — it has decreased -0.15 % in the last trading day.

What is Immunocore Holdings PLC (IMCR)'s business?

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

What is the price predicton of IMCR Stock?

What is Immunocore Holdings PLC (IMCR)'s revenue for the last quarter?

Immunocore Holdings PLC revenue for the last quarter amounts to 103.69M USD, increased 29.22 % YoY.

What is Immunocore Holdings PLC (IMCR)'s earnings per share (EPS) for the last quarter?

Immunocore Holdings PLC. EPS for the last quarter amounts to -0.00 USD, decreased -100.00 % YoY.

What changes have occurred in the market's expectations for Immunocore Holdings PLC (IMCR)'s fundamentals?

How many employees does Immunocore Holdings PLC (IMCR). have?

Immunocore Holdings PLC (IMCR) has 493 emplpoyees as of January 10 2026.

What is Immunocore Holdings PLC (IMCR) market cap?

Today IMCR has the market capitalization of 1.67B USD.